Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
26 Abril 2024 - 8:57AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
| | | | | | | | |
Filed by the Registrant þ | | Filed by a Party other than the Registrant o |
Check the appropriate box:
| | | | | |
| o | Preliminary Proxy Statement |
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| o | Definitive Proxy Statement |
| þ | Definitive Additional Materials |
| o | Soliciting Material Pursuant to § 240.14a-12 |
CARTESIAN THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
| | | | | | | | | | | | | | |
| Payment of Filing Fee (Check the appropriate box) |
| þ | | | | No fee required. |
| o | | | | Fee previously paid with preliminary materials |
| o | | | | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Selecta Biosciences (NASDAQ:SELB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Selecta Biosciences (NASDAQ:SELB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
